Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Metformin/Vildagliptin 1000/50 mg vs EUCREAS in Healthy Fed Males
NCT05329857Phase 1Completed
- Sponsor
- AET Laboratories Private Limited
- Start
- Dec 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of vildagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AET Laboratories Private Limited. Primary endpoints: Maximum Plasma Concentration up to 24 hours and Area Under the Curve from time 0 to last measurable concentration up to 24 hours. Started Dec 2015; status: completed.
02
Drugs
vildagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05329857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329857.